Generic User Fee Talks Reach 'Final Wording' But Still Not Done
Executive Summary
FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.
You may also be interested in...
GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
Final GDUFA I application fees decrease amid expected boost in submissions, while facility fees will increase for the fourth time in five years.
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.